Ingram Micro Extends Financing Programs and Flexible Credit Options to Technology Channel Partners across Europe
20.5.2020 09:00:00 EEST | Business Wire | Press release
Ingram Micro Inc. today announced another wave of financial services to help channel partners solve for the cash crunch created by the COVID-19 pandemic, while meeting the technology needs of businesses and consumers worldwide. Readily available throughout Europe, the new and enhanced Ingram Micro Financial Solutions offerings include flexible, low-interest and long-term financing solutions, as well as extended credit terms, deferred payments, as-a-service models and pay-as-you-go options.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519006025/en/
Mark Snider, Executive Vice President and Group President, EMEA, Ingram Micro (Photo: Business Wire)
“Ingram Micro is generating new ways to help our channel partners, and the businesses they serve, stay strong, agile and fiscally smart, so they can come out of this crisis in a position of strength,” said Mark Snider, Executive Vice President and Group President, EMEA, Ingram Micro. “Each country throughout Europe is unique, yet many of our channel partners, and their business customers, face similar fiscal and cash flow concerns, due to the economic impact of COVID-19. Fortunately, financial services are one of the many areas where Ingram Micro is clearly differentiated and able to help our channel partners at scale locally and globally.”
In addition, Ingram Micro is also helping channel partners identify and address the European marketplace’s work from home (WFH) and distance learning requirements, as well as cybersecurity-as-a-service, data centre solutions and cloud-based services. “COVID-19 prioritized digital transformation overnight, placing Ingram Micro and our channel partners in a position to serve and help keep the world securely connected and moving forward together,” Snider continued.
John Mayer, Vice President, Channel Financing, Ingram Micro Europe and Asia Pacific adds, “Our financing options are structured to address the present and give businesses a way to prepare for the future—helping our channel partners and the businesses they serve to create and preserve cash, protect credit lines, and align payments to the current business environment, until business activity is more stable and growing.”
Throughout Europe, channel partners are taking advantage of the new Ingram Micro Financial Solutions programs including the purchase and lease back of IT solutions. “Having the flexibility to lease, buy or defer payments is changing the conversation and allowing us to get our customers the technology they need in real-time without taking on the financial risk or using our own cash to close the deal,” says Ingram Micro channel partner Brian Dunleavy, Commercial Director, Viadex UK Ltd.
Channel partners in Europe can also access longer-term financing solutions through IMFS. These solutions will align payments with revised budget objectives and places the needed capital quickly back into business cash reserves. Similarly, Ingram Micro’s “as a service” finance offerings are making it easier for channel partners interested in expanding their managed services business and cloud practices.
“As-a-service financing solutions are easier on budgets, versus capital-intensive one-time technology purchases. This model also establishes a more profitable recurring revenue stream for channel partners,” says Kris Mees, Vice President Finance and International CFO, Ingram Micro Europe. “With the rising adoption of cloud and managed services, we expect our “as-a-service” financing options to gain more traction, and we’re ready to give channel partners, and the businesses they serve the support they need.”
Additionally, Ingram Micro credit and financial experts are working one-on-one with qualified channel partners across Europe to determine what other offerings may be available to them including custom financing solutions and additional credit capacity. Ingram Micro Europe’s standard suite of financial services and solutions includes:
- Traditional leasing
- Advanced solutions financing
- Managed services financing
- Private-label agreements
- And, financial structures such as fair market value, full pay out, technology equipment rentals, pay-as-you-grow solutions, and guaranteed purchase options
“Today and every day, helping our channel partners understand the financing options available to them and their customers is equally as important as helping them decide on what technology solutions and services are best suited for the needs of their customers,” concludes Mayer. “Together with our channel partners, we will continue to grow and create sustainable business value that leads to an exceptional experience for them and their customers.”
Ingram Micro Financial Solutions operates globally offering financial programs and services across the Americas, Asia Pacific and Europe. To find out more about the financial solutions in Europe, please contact: https://financing.ingrammicro.eu/.
About Ingram Micro
Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables its business partners to operate efficiently and successfully in the markets they serve. Unparalleled agility, deep market insights and the trust and dependability that come from decades of proven relationships, set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519006025/en/
Contact information
Marie Rourke
WhiteFox Marketing Inc.
marie@whitefoxpr.com
714-292-2199
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
